Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Conditions
- Blastoid Variant Mantle Cell Lymphoma
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Follicular Lymphoma
- Recurrent Hodgkin Lymphoma
- Recurrent Mantle Cell Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Follicular Lymphoma
- Refractory Hodgkin Lymphoma
- Refractory Mantle Cell Lymphoma
Interventions
- DRUG: Ibrutinib
- OTHER: Laboratory Biomarker Analysis
Sponsor
Vanderbilt-Ingram Cancer Center
Collaborators